Aptose Biosciences Unveils Promising AML Therapy Data

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off The latest update is out from Aptose Biosciences ( (TSE:APS) ). On December 6, 2025, Aptose Biosciences presented promising clinical data at the 2025 ASH Annual Meeting for its lead compound tuspetinib (TUS) combined with venetoclax (VEN) and azacitidine (AZA) in treating newly diagnosed AML patients. The TUS+VEN+AZA triplet therapy demonstrated high efficacy and safety, achieving a 100% response rate at higher dose levels and showing effectiveness across diverse genetic mutations, including difficult-to-treat subgroups. The therapy was well tolerated with no dose-limiting toxicities, and early data from the TUSCANY trial supports its use across a broad range of AML populations, potentially impacting the company’s market positioning and offering new hope for stakeholders in the AML treatment landscape. The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.41 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page. Spark’s Take on TSE:APS Stock According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform. Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments. To see Spark’s full report on TSE:APS stock, click here. More about Aptose Biosciences Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. The company’s pipeline includes small molecule cancer therapeutics designed to provide efficacy as single agents and enhance the efficacy of other anti-cancer therapies without overlapping toxicities. Their lead compound, tuspetinib (TUS), is an oral kinase inhibitor being developed for use in patients with relapsed or refractory acute myeloid leukemia (AML) and as a frontline triplet therapy in newly diagnosed AML. YTD Price Performance: -77.13% Average Trading Volume: 4,352 Technical Sentiment Signal: Sell Current Market Cap: C$5.69M